hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Gancao Nurish-Yin Decoction medicated serum inhibits growth and migration of ovarian cancer cells: Network pharmacology-based analysis and biological validation
Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, P.R. China.
Jinan University, Guangzhou, P.R. China.
Karolinska Institutet, Stockholm, Sweden; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, P.R. China.ORCID iD: 0000-0001-7790-8197
Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Guangzhou, P.R. China.
2022 (English)In: Pharmacological Research - Modern Chinese Medicine, E-ISSN 2667-1425, Vol. 2, article id 100062Article in journal (Refereed) Published
Abstract [en]

Ovarian cancer is one of the leading causes of death in women. It is also an important factor for an increased worldwide gynecological death observed recently. Here, we have elucidated the effect and mechanisms of Gancao Nurish-Yin Decoction (GNYD) on the viability of ovarian cancer cells. Network pharmacology analysis was performed to explore the putative therapeutic targets of GNYD on the ovarian cancer cells. Experiments at the cellular and molecular levels using ovarian cancer cells were performed to further verify the effect of GNYD. According to the network pharmacology analysis, 282 genes related to the targets of GNYD were identified. Among them, 123 genes were found to be overlapping as the potential targets for treating ovarian cancer. Subsequent experiments proved that GNYD medicated serum has significantly inhibited the survival, growth and migration of the ovarian cancer cells. The number of apoptotic cells has increased after the treatment with GNYD medicated serum, and a higher proportion of cells were arrested at G2/M phase. Importantly, genes present in the AMPK-p53/p21 pathway were found to be significantly promoted. Thus, this study has not only demonstrated the potential therapeutic value of GNYD in inhibiting the survival, growth and migration of ovarian cancer cells in vitro, but also provide clues for further exploring the pharmacological and molecular mechanisms of Chinese medicine preparations acting on various types of cancer. © 2022 The Authors. 

Place, publisher, year, edition, pages
Beijing: Elsevier, 2022. Vol. 2, article id 100062
Keywords [en]
Network pharmacology, Ovarian cancer, Herbal medicine, Medicated serum
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:hh:diva-48345DOI: 10.1016/j.prmcm.2022.100062OAI: oai:DiVA.org:hh-48345DiVA, id: diva2:1702720
Note

The work was supported by China Postdoctoral Science Foundation Project (2021M701438).

Available from: 2022-10-11 Created: 2022-10-11 Last updated: 2022-11-09Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records

Nandakumar, Kutty Selva

Search in DiVA

By author/editor
Nandakumar, Kutty Selva
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 13 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf